Patient outcome according to random assignment for lenalidomide maintenance or observation
| . | Observation . | Lenalidomide maintenance . | Cox regression* . | ||
|---|---|---|---|---|---|
| HR . | 95% CI . | P . | |||
| Total | 43 (100) | 45 (100) | |||
| Outcomes | |||||
| Relapse after second randomization | 12 (28) | 11 (24) | |||
| Death after second randomization | 8 (19) | 4 (9) | |||
| Relapse-free mortality after second randomization | 2 (5) | — | |||
| At 3 years (% ± SE): | |||||
| CIR† | 34 ± 10 | 28 ± 8 | 0.81 | 0.36-1.85 | .62 |
| RFS† | 67 ± 7 | 75 ± 6 | 0.70 | 0.32-1.55 | .38 |
| OS† | 84 ± 6 | 91 ± 4 | 0.51 | 0.15-1.72 | .28 |
| MRD positive | |||||
| Before second randomization | 2 (5) | 4 (9) | |||
| After second randomization | 2 (5) | 1 (2) | |||
| . | Observation . | Lenalidomide maintenance . | Cox regression* . | ||
|---|---|---|---|---|---|
| HR . | 95% CI . | P . | |||
| Total | 43 (100) | 45 (100) | |||
| Outcomes | |||||
| Relapse after second randomization | 12 (28) | 11 (24) | |||
| Death after second randomization | 8 (19) | 4 (9) | |||
| Relapse-free mortality after second randomization | 2 (5) | — | |||
| At 3 years (% ± SE): | |||||
| CIR† | 34 ± 10 | 28 ± 8 | 0.81 | 0.36-1.85 | .62 |
| RFS† | 67 ± 7 | 75 ± 6 | 0.70 | 0.32-1.55 | .38 |
| OS† | 84 ± 6 | 91 ± 4 | 0.51 | 0.15-1.72 | .28 |
| MRD positive | |||||
| Before second randomization | 2 (5) | 4 (9) | |||
| After second randomization | 2 (5) | 1 (2) | |||